COMPANY

Aethlon Medical, Inc.

HQ: San Diego, CA source · aethlonmedical.com ↗ · West Coast

Keywords: oncology infectious disease cancer solid tumors Squamous Cell Carcinoma of the Head and Neck COVID-19 End Stage Renal Disease Hepatitis C Infection melanoma breast cancer Hemopurifier Affinity plasmapheresis

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)3NIH grants

Funding and NIH signals

SEC Form D raise Raised $2.15M (Form D filed Dec 23, 2025). SEC Form D 0000882291-25-000004 (Dec 23, 2025)
Evidence (1 event)
- Dec 23, 2025 · SEC Form D 0000882291-25-000004
  Name of Issuer: AETHLON MEDICAL INC; CIK: 882291; Address: San Diego, CA; Submission type: D; Filing date: 2025-12-23; Industry Group: Biotechnology; Date of First Sale: 2025-12-08; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 2153700; Total Amount Sold: 2153700; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jun 1, 2022 Trial start Not phased (device or behavioral study): Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device source ↗
Oct 22, 2020 Trial start Not phased (device or behavioral study): Hemopurifier Plus Pembrolizumab in Head and Neck Cancer source ↗
2014-12 Trial start Not phased (device or behavioral study): Safety Study of the Aethlon Hemopurifier source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT04453046	Hemopurifier Plus Pembrolizumab in Head and Neck Cancer	Not phased (device or behavioral study)	Terminated	Oct 22, 2020	Nov 14, 2022 (actual)
NCT04595903	Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device	Not phased (device or behavioral study)	Terminated	Jun 1, 2022	Nov 14, 2022 (actual)
NCT02215902	Safety Study of the Aethlon Hemopurifier	Not phased (device or behavioral study)	Terminated	2014-12	Mar 10, 2017 (actual)

NIH awards 3

Annual award amounts. Total $2.5M.

2019 NIH contract (government contract; not a grant and not an investment round) 75N91019C00042-0-9999-1 FY2019: $1,860,561 awarded for that fiscal year; activity N44 (OTHER_NIH); PI MARLEAU, ANNETTE; recipient as written: AETHLON MEDICAL, INC., SAN DIEGO, CA. Topi source ↗
Sep 14, 2018 NIH award 1R43CA232977-01 FY2018: $298,444 awarded for that fiscal year; activity R43 (SBIR); PI MARLEAU, ANNETTE; recipient as written: AETHLON MEDICAL, INC., SAN DIEGO, CA. The Hemopurifier Device for Targeted Remo source ↗
2017 NIH contract (government contract; not a grant and not an investment round) 261201700022C-0-0-1 FY2017: $299,250 awarded for that fiscal year; activity N43 (OTHER_NIH); PI MARLEAU, ANNETTE; recipient as written: AETHLON MEDICAL, INC., SAN DIEGO, CA. IGF::OT::I source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-12-23 Raise Private raise (SEC Form D): $2.2M sold; issuer “AETHLON MEDICAL INC”. Verified from the SEC filing. SEC filing ↗